Increased binding of peripheral benzodiazepine receptor in mild cognitive impairment-dementia converters measured by positron emission tomography with [11C]DAA1106

Psychiatry Research - Neuroimaging

Volumn 203, Issue 1, 2012, Pages 67-74

  Yasuno, Fumihiko ^a,c   Kosaka, Jun ^a   Ota, Miho ^a,b   Higuchi, Makoto ^a   Ito, Hiroshi ^a   Fujimura, Yota ^a   Nozaki, Shoko ^a   Takahashi, Sho ^b   Mizukami, Katsuyoshi ^b   Asada, Takashi ^b   Suhara, Tetsuya ^a  

^a NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

^b UNIVERSITY OF TSUKUBA   (Japan)

^c NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

Author keywords

11C DAA1106; Alzheimer's disease (AD); Microglia; Mild cognitive impairment (MCI); Peripheral benzodiazepine receptor (PBR); Positron emission tomography

Indexed keywords

(N 5 FLUORO 2 PHENOXYPHENYL) N (2,5 DIMETHOXYL BENZYL) ACETAMIDE; ACETAMIDE; BENZODIAZEPINE RECEPTOR; CARBON 11; UNCLASSIFIED DRUG;

ADULT; AGE DISTRIBUTION; AGED; ALZHEIMER DISEASE; ARTICLE; BINDING AFFINITY; CELL ACTIVATION; CLINICAL ARTICLE; CONTROLLED STUDY; DEMENTIA; FEMALE; HUMAN; IN VIVO STUDY; MALE; MICROGLIA; MILD COGNITIVE IMPAIRMENT; NEUROLOGIC EXAMINATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE ANALYSIS; RECEPTOR BINDING; RISK ASSESSMENT;

ACETAMIDES; AGED; ALZHEIMER DISEASE; BRAIN; CASE-CONTROL STUDIES; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MICROGLIA; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; PHENYL ETHERS; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOLIGAND ASSAY; RADIOPHARMACEUTICALS; RECEPTORS, GABA;

EID: 84866291187     PISSN: 09254927     EISSN: 18727506     Source Type: Journal    
DOI: 10.1016/j.pscychresns.2011.08.013     Document Type: Article

References (50)

1. Banati R., Newcombe J., Gunn R., Cagnin A., Turkheimer F., Heppner F., Price G., Wegner F., Giovannoni G., Miller D.H., Perkin G.D., Smith T., Hewson A.K., Bydder G., Kreutzberg G.W., Jones T., Cuzner M.L., Myers R. The peripheral benzodiazepine binding site in the brain in multiple sclerosis: quantitative in vivo imaging of microglia as a measure of disease activity. Brain 2000, 123:2321-2337.
2. Barger S., Harmon A. Microglial activation by Alzheimer amyloid precursor protein and modulation by apolipoprotein E. Nature 1997, 388:878-881.
3. Cagnin A., Brooks D., Kennedy A., Gunn R., Myers R., Turkheimer F., Jones T., Banati R.B. In-vivo measurement of activated microglia in dementia. Lancet 2001, 358:461-467.
4. 3H]DAA1106, a novel and selective ligand for peripheral benzodiazepine receptors. European Journal of Pharmacology 1999, 371:197-204.
5. 11C-PK11195 in a rat model of acute neuroinflammation. Journal of Nuclear Medicine 2009, 50:468-476.
6. Chen M., Guilarte T. Imaging the peripheral benzodiazepine receptor response in central nervous system demyelination and remyelination. Toxicological Sciences 2006, 91:532-539.
7. Chen M., Baidoo K., Verina T., Guilarte T. Peripheral benzodiazepine receptor imaging in CNS demyelination: functional implications of anatomical and cellular localization. Brain 2004, 127:1379-1392.
8. Cummings B.J., Su J.H., Geddes J.W., Van Nostrand W.E., Wagner S.L., Cunningham D.D., Cotman C.W. Aggregation of the amyloid precursor protein within degenerating neurons and dystrophic neurites in Alzheimer's disease. Neuroscience 1992, 48:763-777.
9. Cunningham V., Lammertsma A. Radioligand studies in brain: kinetic analysis of PET data. Medicinal Chemistry Research 1995, 5:79-96.
10. 11C]PK11195 in normal human brain and application in multiple sclerosis patients. Acta Neurologica Belgica 2002, 102:127-135.
11. Diorio D., Welner S., Butterworth R., Meaney M., Suranyi-Cadotte B. Peripheral benzodiazepine binding sites in Alzheimer's disease frontal and temporal cortex. Neurobiology of Aging 1991, 12:255-258.
12. 123I]iodo-PK11195: a possible single-photon emission tomography tracer for visualization of inflammation. European Journal of Nuclear Medicine 1999, 26:194-200.
13. el Hachimi K., Foncin J. Do microglial cells phagocyte the beta/A4-amyloid senile plaque core of Alzheimer disease?. Comptes Rendus de l'Académie des Sciences. Série III 1994, 317:445-451.
14. Eriksson L., Holte S., Bohm C., Kesselberg M., Hovander B. Automated blood sampling systems for positron emission tomography. IEEE Transactions on Nuclear Science 1988, 35:703-707.
15. Frackowiak J.W.H., Wegiel J., Merz G., Iqbal K., Wang K. Ultrastructure of the microglia that phagocytose amyloid and the microglia that produce beta-amyloid fibrils. Acta Neuropathologica (Berlin) 1992, 84:225-233.
16. 18F-PBR06. Journal of Nuclear Medicine 2009, 50:1047-1053.
17. Fujita M., Imaizumi M., Zoghbi S.S., Fujimura Y., Farris A.G., Suhara T., Hong J., Pike V.W., Innis R.B. Kinetic analysis in healthy humans of a novel positron emission tomography radioligand to image the peripheral benzodiazepine receptor, a potential biomarker for inflammation. NeuroImage 2008, 40:43-52.
18. 11C](R)-PK11195 PET study. NeuroImage 2005, 24:591-595.
19. 11C](R)-PK11195 positron emission tomography. American Journal of Roentgenology 2001, 176:1016-1018.
20. 11C]vinpocetine: a prospective peripheral benzodiazepine receptor ligand for primate PET studies. Journal of the Neurological Sciences 2005, 15:219-223.
21. Gulyás B., Makkai B., Kása P., Gulya K., Bakota L., Várszegi S., Beliczai Z., Andersson J., Csiba L., Thiele A., Dyrks T., Suhara T., Suzuki K., Higuchi M., Halldin C. A comparative autoradiography study in post mortem whole hemisphere human brain slices taken from Alzheimer patients and age-matched controls using two radiolabelled DAA1106 analogues with high affinity to the peripheral benzodiazepine receptor (PBR) system. Neurochemistry International 2009, 54:28-36.
22. Hashimoto K., Inoue O., Suzuki K., Yamasaki T., Kojima M. Synthesis and evaluation of 11C-PK 11195 for in vivo study of peripheral-type benzodiazepine receptors using positron emission tomography. Annals of Nuclear Medicine 1989, 3:63-71.
23. 11C]DAA1106. Journal of Cerebral Blood Flow and Metabolism 2007, 27:173-184.
24. Ji B., Maeda J., Sawada M., Ono M., Okauchi T., Inaji M., Zhang M.R., Suzuki K., Ando K., Staufenbiel M., Trojanowski J.Q., Lee V.M., Higuchi M., Suhara T. Imaging of peripheral benzodiazepine receptor expression as biomarkers of detrimental versus beneficial glial responses in mouse models of Alzheimer's and other CNS pathologies. The Journal of Neuroscience 2008, 28:12255-12267.
25. Kuhlmann A., Guilarte T. Cellular and subcellular localization of peripheral benzodiazepine receptors after trimethyltin neurotoxicity. Journal of Neurochemistry 2000, 74:1694-1704.
26. 11C]DAA1106 for PET: an imaging tool for glial cells in the brain. Synapse 2004, 52:283-291.
27. Maeda J., Higuchi M., Inaji M., Ji B., Haneda E., Okauchi T., Zhang M., Suzuki K., Suhara T. Phase-dependent roles of reactive microglia and astrocytes in nervous system injury as delineated by imaging of peripheral benzodiazepine receptor. Brain Research 2007, 1157:100-111.
28. Maeda J., Zhang M.R., Okauchi T., Ji B., Ono M., Hattori S., Kumata K., Iwata N., Saido T.C., Trojanowski J.Q., Lee V.M., Staufenbiel M., Tomiyama T., Mori H., Fukumura T., Suhara T., Higuchi M. In vivo positron emission tomography imaging of glial response to amyloid-βand tau pathologies in mouse models of Alzheimer's disease and related disorders. The Journal of Neuroscience 2011, 31:4720-4730.
29. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984, 34:939-944.
30. Morris J. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993, 43:2412-2414.
31. Okello A., Edison P., Archer H.A., Turkheimer F.E., Kennedy J., Bullock R., Walker Z., Kennedy A., Fox N., Rossor M., Brooks D.J. Microglial activation and amyloid deposition in mild cognitive impairment: a PET study. Neurology 2009, 72:56-62.
32. Okuyama S., Chaki S., Yoshikawa R., Ogawa S., Suzuki Y., Okubo T., Nakazato A., Nagamine M., Tomisawa K. Neuropharmacological profile of peripheral benzodiazepine receptor agonists, DAA1097 and DAA1106. Life Sciences 1999, 64:1455-1464.
33. Owen D.R., Gunn R.N., Rabiner E.A., Bennacef I., Fujita M., Kreisl W.C., Innis R.B., Pike V.W., Reynolds R., Matthews P.M., Parker C.A. Mixed-affinity binding in humans with 18-kDa translocator protein ligands. Journal of Nuclear Medicine 2011, 52:24-32.
34. Petersen R.C. Mild cognitive impairment as a diagnostic entity. Journal of Internal Medicine 2004, 256:183-194.
35. Petersen R.C., Parisi J.E., Dickson D.W., Johnson K.A., Knopman D.S., Boeve B.F., Jicha G.A., Ivnik R.J., Smith G.E., Tangalos E.G., Braak H., Kokmen E. Neuropathologic features of amnestic mild cognitive impairment. Archives of Neurology 2006, 63:665-672.
36. Price C., Wang D., Menon D., Guadagno J., Cleij M., Fryer T., Aigbirhio F., Baron J., Warburton E. Intrinsic activated microglia map to the peri-infarct zone in the subacute phase of ischemic stroke. Stroke 2006, 37:1749-1753.
37. 11C]PK11195 by PET and induction of the peripheral-type benzodiazepine receptor after transient focal ischemia in rats. Journal of Cerebral Blood Flow and Metabolism 2007, 27:1975-1986.
38. Roman G.C., Tatemichi T.K., Erkinjuntti T., Cummings J.L., Masdeu J.C., Garcia J.H., Amaducci L., Orgogozo J.M., Brun A., Hofman A. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 1993, 43:250-260.
39. Sette G., Baron J., Young A., Miyazawa H., Tillet I., Barre L., Travere J., Derlon J., MacKenzie E. In vivo mapping of brain benzodiazepine receptor changes by positron emission tomography after focal ischemia in the anesthetized baboon. Stroke 1993, 24:2046-2057.
40. Tan J., Town T., Paris D., Mori T., Suo Z., Crawford F., Mattson M.P., Flavell R.A., Mullan M. Microglial activation resulting from CD40-CD40L interaction after beta-amyloid stimulation. Science 1999, 286:2352-2355.
41. Tan J., Town T., Crawford F., Mori T., DelleDonne A., Crescentini R., Obregon D., Flavell R.A., Mullan M.J. Role of CD40 ligand in amyloidosis in transgenic Alzheimer's mice. Nature Neuroscience 2002, 5:1288-1293.
42. Versijpt J., Dumont F., Van Laere K., Decoo D., Santens P., Audenaert K., Achten E., Slegers G., Dierckx R.A., Korf J. Assessment of neuroinflammation and microglial activation in Alzheimer's disease with radiolabelled PK11195 and single photon emission computed tomography. A pilot study. European Neurology 2003, 50:39-47.
43. Wisniewski H., Wegiel J., Wang K., Lach B. Ultrastructural studies of the cells forming amyloid in the cortical vessel wall in Alzheimer's disease. Acta Neuropathologica (Berlin) 1992, 84:117-127.
44. Wyss-Coray T. Inflammation in Alzheimer disease: driving force, bystander or beneficial response?. Nature Medicine 2006, 12:1005-1015.
45. Yasuno F., Hasnine A., Suhara T., Ichimiya T., Sudo Y., Inoue M., Takano A., Ou T., Ando T., Toyama H. Template-based method for multiple volumes of interest of human brain PET images. NeuroImage 2002, 16:577-586.
46. 18F]SPA-RQ in human subjects: assessment of reference tissue models and their test-retest reproducibility. Synapse 2007, 61:242-251.
47. 11C]DAA1106. Biological Psychiatry 2008, 64:835-841.
48. Yokokura M., Mori N., Yagi S., Yoshikawa E., Kikuchi M., Yoshihara Y., Wakuda T., Sugihara G., Takebayashi K., Suda S., Iwata Y., Ueki T., Tsuchiya K.J., Suzuki K., Nakamura K., Ouchi Y. In vivo changes in microglial activation and amyloid deposits in brain regions with hypometabolism in Alzheimer's disease. European Journal of Nuclear Medicine and Molecular Imaging 2011, 38:343-351.
49. Yoshiyama Y., Higuchi M., Zhang B., Huang S.M., Iwata N., Saido T.C., Maeda J., Suhara T., Trojanowski J.Q., Lee V.M. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 2007, 53:337-351.
50. 11C]DAA1106: radiosynthesis and in vivo binding to peripheral benzodiazepine receptors in mouse brain. Nuclear Medicine and Biology 2003, 30:513-519.